Back
Alnylam Pharmaceuticals, Inc. 10K Form
Buy
63
ALNY
Alnylam Pharmaceuticals, Inc.
Last Price:
$465.37
Seasonality Move:
6.39%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-05-02 | 10Q | ALNY/Alnylam Pharmaceuticals, Inc. Quarterly |
| 2023-11-02 | 10Q | ALNY/Alnylam Pharmaceuticals, Inc. Quarterly |
| 2023-08-03 | 10Q | ALNY/Alnylam Pharmaceuticals, Inc. Quarterly |
| 2023-05-04 | 10Q | ALNY/Alnylam Pharmaceuticals, Inc. Quarterly |
| 2022-10-27 | 10Q | ALNY/Alnylam Pharmaceuticals, Inc. Quarterly |
| 2022-07-28 | 10Q | ALNY/Alnylam Pharmaceuticals, Inc. Quarterly |
Receive ALNY News And Ratings
See the #1 stock for the next 7 days that we like better than ALNY
ALNY Financial Statistics
Sales & Book Value
| Annual Sales: | $2.2B |
|---|---|
| Cash Flow: | $313M |
| Price / Cash Flow: | 276.84 |
| Annual Sales: | $1.77 |
| Price / Book: | 262.85 |
Profitability
| EPS (TTM): | 0.24050 |
|---|---|
| Net Income (TTM): | $43.6M |
| Gross Margin: | $1.9B |
| Return on Equity: | 31.15% |
| Return on Assets: | 0.98% |
Alnylam Pharmaceuticals, Inc. Earnings Forecast
Key Alnylam Pharmaceuticals, Inc. Financial Ratios
-
The Gross Profit Margin over the past 20 years for ALNY is 85.62%.
-
The Selling, General & Administrative Expenses for ALNY have been equal to 43.39% of Gross Profit Margin.
-
The Research & Development expenses have been 50.09% of Revenue.
-
The Net Earning history of ALNY is -12.37% of Total Revenues.
-
Per Share Earnings over the last 23 years have been positive in 11 years.
Alnylam Pharmaceuticals, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | ALNY |
| CUSIP: | 02043Q |
| Website: | alnylam.com |
Debt
| Debt-to-Equity Ratio: | 11.86 |
|---|---|
| Current Ratio: | 2.54 |
| Quick Ratio: | 2.37 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 43.86 |
ALNY Technical Analysis vs Fundamental Analysis
Buy
63
Alnylam Pharmaceuticals, Inc. (ALNY)
is a Buy
Is Alnylam Pharmaceuticals, Inc. a Buy or a Sell?
-
Alnylam Pharmaceuticals, Inc. stock is rated a BuyThe current Alnylam Pharmaceuticals, Inc. [ALNY] share price is $465.34. The Score for ALNY is 63, which is 26% above its historic median score of 50, and infers lower risk than normal.